10 Micro-Cap Stocks Insiders Were Buying in Q1 2025

5. biote Corp. (NASDAQ:BTMD)

Number of insiders buying: 5

Market Capitalization: $192.84 million

Biote specializes in hormone optimization, offering training and certification for physicians and nurse practitioners in bioidentical hormone replacement therapy. It ranks fifth among the 10 micro-cap stocks insiders were buying in Q1 2025.

The Irving, Texas-based company provides a comprehensive practice-building platform, including education, practice management software, inventory tools, and marketing support. Biote also sells dietary supplements and sterile pellet insertion kits for hormone therapy.

In March, five insiders, including the company’s CEO, acquired a total of $2.79 million worth of biote shares at an average price of $3.75 per share. Currently, the stock trades at $3.63 per share, having dropped 41.26% year-to-date and 37.09% over the past 12 months.

For the full year 2024, biote disclosed revenue of $197.2 million, up 6.4% year-over-year. The increase was primarily driven by growth in procedure revenue. Net income attributable to biote stockholders amounted to $3.16 million, compared to $3.32 million in 2023. Gross profit margin for 2024 was 70.5% compared to 68.8% for 2023. The increase in gross profit margin was primarily due to the vertical integration of its 503B manufacturing facility and effective cost management. Adjusted EBITDA for 2024 was $58.2 million, with an adjusted EBITDA margin of 29.5%, compared to adjusted EBITDA of $55.3 million, with an adjusted EBITDA margin of 29.8% for 2023.

The consensus rating on biote stock from six analysts is a “Strong Buy” with a price target of $7.36 per share, reports TipRanks. The average price target suggests a 102.75% upside from the latest price.